A microfluidic chip developed at the University of Michigan is among the best at capturing elusive circulating tumor cells from blood—and it can support the cells’ growth for further analysis.
The device, believed to be the first to pair these functions, uses the advanced electronics material graphene oxide. In clinics, such a device could one day help doctors diagnose cancers, give more accurate prognoses and test treatment options on cultured cells without subjecting patients to traditional biopsies.
“If we can get these technologies to work, it will advance new cancer drugs and revolutionize the treatment of cancer patients,” said Max Wicha, M.D., Distinguished Professor of Oncology and director of the U-M Comprehensive Cancer Center and co-author of a paper on the new device, published online this week in Nature Nanotechnology.
“Circulating tumor cells will play a significant role in the early diagnosis of cancer and to help us understand if treatments are working in our cancer patients by serving as a ‘liquid’ biopsy to assess treatment responses in real time,” said co-author Dr. Diane Simeone, the Lazar J. Greenfield Professor of Surgery at the U-M Medical School and director of the Translational Oncology Program.
“Studies of circulating tumor cells will also help us understand the basic biologic mechanisms by which cancer cells metastasize or spread to distant organs—the major cause of death in cancer patients.”
Yet these cells aren’t living up to their promise in medicine because they are so difficult to separate from a blood sample, the researchers say. In the blood of early-stage cancer patients, they account for less than one in every billion cells, so catching them is tougher than finding the proverbial needle in a haystack.
“I can burn the haystack or use a huge magnet,” said Sunitha Nagrath, an assistant professor of chemical engineering, who led the research. “When it comes to circulating tumor cells, they almost look like—feel like—any other blood cell.”
On their microfluidic chip, Nagrath’s team grew dense forests of molecular chains, each equipped with an antibody to grab onto cancer cells.
Even after the cells are caught, it’s still hard to run a robust analysis on just a handful of them, the researchers say. That’s why this demonstration of highly sensitive tumor cell capture, combined with the ability to grow the cells in the same device, is so promising.
Hyeun Joong Yoon, a postdoctoral researcher in the Nagrath lab with a background in electrical engineering, was instrumental in making the microfluidic chip. He started with a silicon base and added a grid of nearly 60,000 flat gold shapes, like four-petaled flowers, each no wider than a strand of hair.
The gold flowers naturally attracted a relatively new material called graphene oxide. These sheets of carbon and oxygen, just a few atoms thick, layered themselves over the gold. This layered formation allowed the team to grow the tumor-cell-catching molecular chains so densely.
“It’s almost like each graphene has many nano-arms to capture cells,” Nagrath said.
To test the device, the team ran one-milliliter samples of blood through the chip’s thin chamber. Even when they had added just three-to-five cancer cells to the 5-10 billion blood cells, the chip was able to capture all of the cells in the sample half the time, with an average of 73 percent over 10 trials.
“That’s the highest anybody has shown in the literature for spiking such a low number of cells,” Nagrath said.
The Latest on: Liquid biopsy
Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform
on June 13, 2019 at 5:00 pm
ANN ARBOR, Mich., June 13, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it has ... […]
Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023
on June 13, 2019 at 1:58 pm
NEW YORK, June 13, 2019 /PRNewswire/ -- Report Scope: The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding ... […]
Noninvasive Cytophone device detects melanoma in earliest stages, could prevent fatal disease spread
on June 13, 2019 at 5:03 am
The team's findings titled "In Vivo Liquid Biopsy using Cytophone Platform for Photoacoustic Detection of Circulating Tumor Cells in Melanoma Patients" were published in the June 12 issue of ... […]
What Should Investors Make of Guardant Health's Newest Competitor?
on June 11, 2019 at 4:32 am
The start-up is developing a liquid biopsy diagnostic called CancerSEEK, which works similar to tests from the publicly traded peer. It detects cancer-specific genetic mutations in ctDNA that can be ... […]
Liquid Biopsy Market to Cross US$9071.7 Million by 2026, Says TMR
on June 10, 2019 at 7:35 am
ALBANY, New York, June 10, 2019 /PRNewswire/ -- TMR predicts that the global liquid biopsy market, which was estimated to be worth US$3,883.2 mn, is projected to reach US$9071.7 mn by 2026. The global ... […]
Global Breast Cancer Liquid Biopsy Market 2018 Sales Revenue, Development Strategy, Competitive Landscape and Regional Forecast to 2025
on June 10, 2019 at 12:33 am
Jun 10, 2019 (Aperture Games via COMTEX) -- Global Breast Cancer Liquid Biopsy Market released by Fior Markets aims to provide Breast Cancer Liquid Biopsy market size, vendor landscape, key leading ... […]
Inivata CEO: ‘Exciting time’ for liquid biopsy in oncology
on June 8, 2019 at 5:09 am
CHICAGO — Clive Morris, MD, CEO of Inivata, spoke with HemOnc Today at ASCO Annual Meeting about the company’s efforts to develop new clinical applications for liquid biopsy and circulating tumor DNA ... […]
Liquid Biopsy Test to Find All Cancers Is Out of Reach for 2019
on June 7, 2019 at 5:12 am
What if a simple blood test could tell if you had cancer? Grail Inc. -- founded by Illumina Inc. and backed by both Jeff Bezos and Bill Gates -- has been targeting just that, but after some early hype ... […]
In a surprise, Hans Bishop takes over as CEO of Grail, the liquid biopsy startup
on June 6, 2019 at 2:19 pm
Grail, the San Francisco company that has raised $1.6 billion to develop a blood test to detect cancer, announced Thursday that it had appointed Hans Bishop, previously the CEO of Juno Therapeutics, ... […]
Meet Thrive: The New Kid on the Liquid Biopsy Block
on June 6, 2019 at 10:42 am
Thrive Earlier Detection Corp. has raised $110 million in a series A financing and has a launch similar to Grail’s introduction into the liquid biopsy market. ... […]
via Google News and Bing News